Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs

This subgroup analysis sought to more fully characterize the demographics, baseline characteristics, safety, and efficacy of
dalbavancin in the persons who inject drugs (PWID) and non-PWID population and as a single-dose therapy versus 2-dose therapy from a previously published global trial.